Xcorporeal (Xcorporeal) ROCE % : 0.00% (As of Sep. 2009)

View and export this data going back to . Start your Free Trial

What is Xcorporeal ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xcorporeal's annualized ROCE % for the quarter that ended in Sep. 2009 was 0.00%.

Xcorporeal ROCE % Historical Data

The historical data trend for Xcorporeal's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal ROCE % Chart

Xcorporeal Annual Data

Trend

Feb99

Feb00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

ROCE %

Get a 7-Day Free Trial

-45.48

-89.87

-432.21

Xcorporeal Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
ROCE %	Get a 7-Day Free Trial															-1,613.72	-2,041.27	-	-	-

Xcorporeal ROCE % Calculation

Xcorporeal's annualized ROCE % for the fiscal year that ended in Dec. 2008 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2008 )		(A: Dec. 2007 )		(A: Dec. 2008 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2008 )		(A: Dec. 2007 )		(A: Dec. 2008 )
	=	-31.893	/	( ( (17.253 - 2.027)	+	(4.351 - 4.819) )	/ 2 )
	=	-31.893	/	( (15.226	+	-0.468)	/ 2 )
	=	-31.893	/	7.379
	=	-432.21 %

Xcorporeal's ROCE % of for the quarter that ended in Sep. 2009 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2009 )		(Q: Jun. 2009 )		(Q: Sep. 2009 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2009 )		(Q: Jun. 2009 )		(Q: Sep. 2009 )
	=	-6.168	/	( ( (1.341 - 3.559)	+	(1.099 - 4.127) )	/ 2 )
	=	-6.168	/	( ( -2.218	+	-3.028 )	/ 2 )
	=	-6.168	/	-2.623
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2009) EBIT data.

Xcorporeal (GREY:XCRP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xcorporeal ROCE % Related Terms

Thank you for viewing the detailed overview of Xcorporeal's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xcorporeal (Xcorporeal) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Empire Drive, Lake Forest, CA, USA, 92630

Website

Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.

Executives

Kelly J. Mccrann	director, officer: Chairman and CEO	11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger	officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins	director	C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc	10 percent owner	135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer	director, 10 percent owner, officer: Executive Chairman	11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf	director	981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen	director	22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte	10 percent owner	C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122